Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Thymus Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Extensive Stage Small Cell Lung Carcinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cytopenia 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × epacadostat × Clear all
NCT03832673 2021-02-26

PECULIAR

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

NCT01685255 2019-03-11

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Incyte Corporation

Phase 2 Terminated
83 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡